Roche has reported positive results from the second year of the EMBARK Phase III trial of Elevidys (delandistrogene moxeparvovec), the first approv ...
Huntington’s disease symptoms are linked to expanding DNA repeats (CAG) that become toxic in brain cells over time The "ticking DNA clock" accelerates after 80 repeats, killing neurons within ...
The following is a summary of “Conventional MRI-Based Structural Disconnection and Morphometric Similarity Networks and Their ...
Brain injuries are a leading cause of death and long-term disability in infants. Among the most common is neonatal ...
A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University, has succeeded in the diagnosis ...
This study presents a valuable finding on the alterations in the autophagic-lysosomal pathway in a Huntington's disease model. The evidence supporting the claims of the authors is solid. However, the ...
The following is a summary of “Brain tissue integrity in neuromyelitis optica spectrum disorder through T1-w/T2-w ratio, MTR ...
A drug originally developed for high blood pressure could find a new use in the treatment of Huntington's disease, thanks to an artificial intelligence-based drug discovery programme at Spain's ...
Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial. Pridopidine is an oral agonist of the S1R protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback